Lek’s Gain is Merck’s Loss as Statin Costs Drop — Panjiva


Lek’s Gain is Merck’s Loss as Statin Costs Drop

Health Care 108 U.S. 3297

Rising U.S. healthcare costs have led President Donald Trump to call for a wide-ranging review of pricing, including the inclusion of international benchmarks as outlined in Panjiva research of Oct. 29. While that has yet to be converted into firm policy there’s likely to be attention focused on the most expensive classes. Among drug imports the second largest class were cardiovascular drugs – including statins – with $5.26 billion of imports in the 12 months to Aug. 31, Panjiva data shows.

Imports of the drugs covered by the class fell 14.7% on a year earlier including a 7.8% rise in volumes, a potential proxy for number of scripts written, and a 22.5% slide in average import values per gram (AIVG).


Chart compares U.S. imports of cardiovascular drugs on a value and average import value per gram (AIVG) basis.   Source: Panjiva

The decline in average import costs and rise in scripts may reflect the availability of generic versions of Merck’s Zetia (ezetimibe) whose original patent ended in April 2017. Subsequent to that the share of ezetimibe imports has risen to 11.5% of total statin imports (covering six major generic drug types) from 1.3% a year earlier. The main losers have been pravastatins (22.1% from 32.5%) and atorvastatins (13.0% from 21.2%).


Chart segments U.S. imports of statin-type drugs by generic name including pravastatins, simvastatins, atorvastatins, rosuvastatins and ezetimibe.   Source: Panjiva

The leading shippers of ezetimibe to the U.S. since August 2017, who are able to profit from the end of Merck’s patent, include Lek Pharma (38.9% of shipments, sourced from Slovenia) and Alkem (27.8%, from India) though Watson, Amneal and Aurobindo also appear to be shipping commercial volumes.


Chart segments U.S. imports of ezetimibe by shipper.   Source: Panjiva

PANJIVA RESEARCH is a service provided by Panjiva, Inc. ("Panjiva") to relevant global subscribers, and are deemed to be Panjiva "Services" subject to the Panjiva Terms & Conditions of Use. Information contained within or made available via the Services is for informational purposes only and nothing in the Services shall constitute or be construed as an offering of financial instruments, or as investment advice or recommendations by Panjiva, Inc. or its affiliates of an investment strategy or whether to "buy", "sell" or "hold" an investment. The Services may include views and commentary about customers of Panjiva. No aspect of the Services is based on consideration of your individual circumstances, and you should determine on your own whether you agree with the information contained within or made available via the Services. Employees involved in Panjiva Research may hold positions in securities analyzed or discussed in the Services. Panjiva does not make any express or implied warranties, representations, endorsements or conditions with respect to the Services and the information contained within or made available via the Services, including without limitation, warranties as to the usefulness, completeness, accuracy, currentness, reliability or sufficiency of any information (including, without limitation, conclusions, statements, opinions, estimates, forecasts or projections of any kind) and expressly disclaims any implied warranties. Neither this disclaimer nor any of its contents may be forwarded or redistributed without the prior written consent of Panjiva. © 2019 Panjiva, Inc. All Rights Reserved.